Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

WALL Street stocks powered to fresh records on Tuesday, shrugging off a threat from President-elect Donald Trump to enact new ...

Shares of weight-loss drugmakers Novo Nordisk and Eli Lilly rose on Tuesday after U.S. President Joe Biden proposed expanding ...

Stocks were higher Tuesday afternoon as investors digested earnings reports from several retailers and awaited results from ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

After Amgen (AMGN) announced topline data from its Phase 2 study of MariTide, the company’s subcutaneously administered GLP-1 weight loss drug, ...

Amgen Obesity Drug Cut Weight In Closely Watched Study Study subjects taking the company's MariTide lost about 20% of their weight in the 52-week trial. Novo Nordisk Says White House Obesity Plan Is ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

Share of Amgen tumbled on Tuesday after the company's experimental weight-loss drug MariTide failed to meet lofty investor ...